APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or Advanced Solid Tumors — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
China
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong Cancer Hospital of The University of Chinese Academy of Sciences, Hangzhou, Zhejiang Shanghai East Hospital (East Hospital affiliated to Tongji University), Shanghai Age range
18 Years and older
Last updated February 2025